2-(3-Butoxy-phenoxymethyl)-quinoline

ID: ALA18775

Chembl Id: CHEMBL18775

PubChem CID: 14650340

Max Phase: Preclinical

Molecular Formula: C20H21NO2

Molecular Weight: 307.39

Molecule Type: Small molecule

Names and Identifiers

Canonical SMILES:  CCCCOc1cccc(OCc2ccc3ccccc3n2)c1

Standard InChI:  InChI=1S/C20H21NO2/c1-2-3-13-22-18-8-6-9-19(14-18)23-15-17-12-11-16-7-4-5-10-20(16)21-17/h4-12,14H,2-3,13,15H2,1H3

Standard InChI Key:  UBDSCBZDTZHXHG-UHFFFAOYSA-N

Alternative Forms

1. Parent:

   

   ALA18775

   2-(3-Butoxy-phenoxymethyl)-quinoline

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 307.39

Molecular Weight (Monoisotopic): 307.1572

AlogP: 4.99

#Rotatable Bonds: 7

Polar Surface Area: 31.35

Molecular Species: NEUTRAL

HBA: 3

HBD: ┄

#RO5 Violations: ┄

HBA (Lipinski): 3

HBD (Lipinski): ┄

#RO5 Violations (Lipinski): ┄

CX Acidic pKa: ┄

CX Basic pKa: 3.17

CX LogP: 4.95

CX LogD: 4.95

Aromatic Rings: 3

Heavy Atoms: 23

QED Weighted: 0.58

Np Likeness Score: -0.83

References

1. Youssefyeh RD, Magnien E, Lee TD, Chan WK, Lin CJ, Galemmo RA, Johnson WH, Tan J, Campbell HF, Huang FC..  (1990)  Development of a novel series of (2-quinolinylmethoxy)phenyl-containing compounds as high-affinity leukotriene receptor antagonists. 1. Initial structure-activity relationships.,  33  (4): [PMID:2157009] [10.1021/jm00166a016]

2. Fiorillo B, Sepe V, Conflitti P, Roselli R, Biagioli M, Marchianò S, De Luca P, Baronissi G, Rapacciuolo P, Cassiano C, Catalanotti B, Zampella A, Limongelli V, Fiorucci S..  (2021)  Structural Basis for Developing Multitarget Compounds Acting on Cysteinyl Leukotriene Receptor 1 and G-Protein-Coupled Bile Acid Receptor 1.,  64  (22.0): [PMID:34767347] [10.1021/acs.jmedchem.1c01078]

Source

Source(1):

• Scientific Literature